Thus, these findings indicate that β-catenin is activated in a subset of human T-ALL cell lines along with NOTCH, AKT and MYC activation, suggesting that pharmacologic inhibition of β-catenin signaling may have significance in a personalized therapeutic setting. Here, MYC is linked to acute lymphoblastic leukemia.